Featured Research

from universities, journals, and other organizations

Iowa Study Advances Understanding Of Antimicrobials And Cystic Fibrosis-Related Infection

Date:
September 9, 1999
Source:
University Of Iowa
Summary:
Human airway secretions include antimicrobial agents that normally protect the lungs from infection caused by inhaled bacteria and other microorganisms. A recent University of Iowa Health Care study suggests that high salt concentrations in the airways of people with cystic fibrosis prevent these antimicrobial factors from working effectively.

IOWA CITY, Iowa -- Human airway secretions include antimicrobial agents that normally protect the lungs from infection caused by inhaled bacteria and other microorganisms. A recent University of Iowa Health Care study suggests that high salt concentrations in the airways of people with cystic fibrosis prevent these antimicrobial factors from working effectively.

"The finding provides some new ideas about treatments for cystic fibrosis," said Sue M. Travis, Ph.D., UI research scientist and principal investigator.

Cystic fibrosis is the most common fatal inherited disease among Caucasians of Northern European descent and occurs in about one of every 2,000 births. Advances in treating the disease complications have increased the average survival age well beyond childhood; however, there is no cure.

In people with cystic fibrosis, whose lungs often become infected by inhaled microorganisms, airway antimicrobial activity has not been well understood. Previous research, including UI studies, showed that cystic fibrosis disrupts defenses against infection because the thin layer of liquid that lines the airways is saltier than in non-cystic fibrosis airways. Under normal conditions, antimicrobial peptides and proteins destroy the invasive microorganisms that land on the airway surface.

"Saltiness impairs the ability of the airway surface liquid to kill bacteria," Travis said. "We investigated specifically whether antimicrobials could kill bacteria in the salty conditions caused by cystic fibrosis."

The investigators studied how previously identified antimicrobial proteins, including lysozyme and lactoferrin, functioned in test-tube samples of human airway secretions taken from healthy people and people with cystic fibrosis.

"We found that the airway secretions, and the individual antimicrobial proteins, could kill bacteria in low-salt conditions, but they were less able to kill bacteria in high-salt concentrations," Travis said. "This inhibition of the antimicrobials by high salt may be why they fail to prevent infections in cystic fibrosis airways."

Travis explained how the findings could lead to potential therapies.

"Lowering the salt concentration in the cystic fibrosis airway might allow the antimicrobial factors to kill bacteria," she said. "Second, treatment using antimocribal factors that can function well in high-salt liquid could be beneficial."

"This work helps lay the foundation on which new treatments can be built for cystic fibrosis," said co-investigator Michael J. Welsh, M.D., UI professor of internal medicine, and physiology and biophysics.

Welsh, who is also a Howard Hughes Medical Institute investigator, led a previous study that suggests that the absence or malfunction of a specialized chloride channel in the cystic fibrosis airway causes the increased saltiness and that treatment could be based on correcting this salt imbalance.

In addition to Travis and Welsh, the other UI investigators for the antimicrobial study included Barbara-Ann D. Conway, Ph.D., postdoctoral associate in microbiology; Joseph Zabner, M.D., assistant professor of internal medicine; Jeffrey J. Smith, M.D., associate professor (clinical) of pediatrics; Norma N. Anderson, researcher in internal medicine; Pradeep K. Singh, M.D., fellow in internal medicine, and E. Peter Greenberg, Ph.D., professor of microbiology.

The study was funded in part by a grant from the Cystic Fibrosis Foundation. The findings were published in the May issue of the American Journal of Respiratory, Cell and Molecular Biology. The May issue also included a perspective on the study by Charles L. Bevins, M.D., Ph.D., of the Lerner Research Institute at the Cleveland Clinic Foundation.


Story Source:

The above story is based on materials provided by University Of Iowa. Note: Materials may be edited for content and length.


Cite This Page:

University Of Iowa. "Iowa Study Advances Understanding Of Antimicrobials And Cystic Fibrosis-Related Infection." ScienceDaily. ScienceDaily, 9 September 1999. <www.sciencedaily.com/releases/1999/09/990909072343.htm>.
University Of Iowa. (1999, September 9). Iowa Study Advances Understanding Of Antimicrobials And Cystic Fibrosis-Related Infection. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1999/09/990909072343.htm
University Of Iowa. "Iowa Study Advances Understanding Of Antimicrobials And Cystic Fibrosis-Related Infection." ScienceDaily. www.sciencedaily.com/releases/1999/09/990909072343.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins